PDCD1 and neoplasm: Immunotherapy, and especially immune checkpoint inhibitor (ICI) antibodies against cytotoxic T-lymphocyte antigen 4 (αCTLA-4) and programmed cell death protein-1 (αPD-1), have proven efficacious in harnessing the immune system to target tumor cells at the level of the tumor microenvironment (TME) [9].